Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Opportunistic infection in inflammatory bowel disease (IBD) has become a serious problem. However, its status of doctors’ opinions and test equipment in hospitals are unclear. The aim of the study was to investigate these issues to improve the prognosis of IBD patients. Methods: This retrospective, multicenter study was conducted by 83 investigators who were members of the Asian Organization for Crohn’s and Colitis. Data on opportunistic infection were collected from hospital databases between January 2017 and December 2017. The survey consisted of 11 items. Results: Most physicians appreciated the diagnostic value of tissue cytomegalovirus (CMV) DNA, accounting for 86.1% of members in China, 37.5% in Japan, 52.9% in South Korea, and 66.7% in Southeast Asia. Only 83.1% of hospitals had the ability to test for CMV immunohistochemistry in Asia. Hepatitis B surface antigen (HBsAg) screening was recommended by all members. However, only 66.7% in China, 70.6% in South Korea, and 66.7% in Southeast Asia agreed to routinely vaccinate IBD patients when HBsAg tested negative. Most members preferred metronidazole (74.7%) as the first choice for patients with Clostridium difficile infection. However, the proportion of stool C. difficile toxin test was lower in China than in other areas (75.0% in China vs 95.8% in Japan and 100% in South Korea and Southeast Asia, p<0.05). Conclusions: Opportunistic infection from CMV, hepatitis B virus, and C. difficile should be of high concern for IBD patients. More efforts are needed, such as understanding consensus in clinical practice and improving testing facilities in hospitals.
Abstract
Background/Aims: Opportunistic infection in inflammatory bowel disease (IBD) has become a serious problem. However, its status of doctors’ opinions and test equipment in hospitals are unclear. The aim of the study was to investigate these issues to improve the prognosis of IBD patients. Methods: This retrospective, multicenter study was conducted by 83 investigators who were members of the Asian Organization for Crohn’s and Colitis. Data on opportunistic infection were collected from hospital databases between January 2017 and December 2017. The survey consisted of 11 items. Results: Most physicians appreciated the diagnostic value of tissue cytomegalovirus (CMV) DNA, accounting for 86.1% of members in China, 37.5% in Japan, 52.9% in South Korea, and 66.7% in Southeast Asia. Only 83.1% of hospitals had the ability to test for CMV immunohistochemistry in Asia. Hepatitis B surface antigen (HBsAg) screening was recommended by all members. However, only 66.7% in China, 70.6% in South Korea, and 66.7% in Southeast Asia agreed to routinely vaccinate IBD patients when HBsAg tested negative. Most members preferred metronidazole (74.7%) as the first choice for patients with Clostridium difficile infection. However, the proportion of stool C. difficile toxin test was lower in China than in other areas (75.0% in China vs 95.8% in Japan and 100% in South Korea and Southeast Asia, p<0.05). Conclusions: Opportunistic infection from CMV, hepatitis B virus, and C. difficile should be of high concern for IBD patients. More efforts are needed, such as understanding consensus in clinical practice and improving testing facilities in hospitals.
참고문헌 (39)
- Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century : a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2017)
- Prideaux L, "Inflammatory bowel disease in Asia : a systematic review", J Gastroenterol Hepatol, 27, pp.1266~1280 (2012)
- Li Y, "Case-control study of inflammatory bowel disease patients with and without Clostridium difficile infection and poor outcomes in patients coinfected with C. difficile and cytomegalovirus", Dig Dis Sci, 63, pp.3074~3083 (2018)
- Xu H, "Retrospective analysis of Clostridium difficile infection in patients with ulcerative colitis in a tertiary hospital in China", BMC Gastroenterol, 19, pp.3~ (2019)
- Sagami S, "Prevention of infectious diseases due to immunosuppression and vaccinations in Asian patients with inflammatory bowel disease", Inflamm Intest Dis, 3, pp.1~10 (2018)
- Schneeweiss S, "Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections", Aliment Pharmacol Ther, 30, pp.253~264 (2009)
- Lichtenstein GR, "Serious infections and mortality in association with therapies for Crohn’s disease : TREAT registry", Clin Gastroenterol Hepatol, 4, pp.621~630 (2006)
- Ng SC, "Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and colitis epidemiology study", Gastroenterology, 145, pp.158~165 (2013)
- McCurdy JD, "Increased rates of Clostridium difficile infection and poor outcomes in patients with IBD with cytomegalovirus", Inflamm Bowel Dis, 22, pp.2688~2693 (2016)
- Kucharzik T, "ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease", J Crohns Colitis, 15, pp.879~913 (2021)
- Inflammatory Bowel Disease Group, "Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)", Intestinal research, 16(2), pp.178~193 (2018), 대한장연구학회
- Papadakis KA, "Outcome of cytomegalovirus infections in patients with inflammatory bowel disease", Am J Gastroenterol, 96, pp.2137~2142 (2001)
- Oh SJ, "True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares : the 10-year experience of an academic referral inflammatory bowel disease center", Scand J Gastroenterol, 54, pp.976~983 (2019)
- Römkens TE, "Cytomegalovirus in inflammatory bowel disease : a systematic review", World J Gastroenterol, 22, pp.1321~1330 (2016)
- Dave M, "Opportunistic infections due to inflammatory bowel disease therapy", Inflamm Bowel Dis, 20, pp.196~212 (2014)
- Hiroshi Nakase, "Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection: Importance of Controlling Mucosal Inflammation to Prevent Cytomegalovirus Reactivation", Intestinal research, 12(1), pp.5~11 (2014), 대한장연구학회
- Yang H, "The association between CMV viremia or endoscopic features and histopathological characteristics of CMV colitis in patients with underlying ulcerative colitis", Inflamm Bowel Dis, 23, pp.814~821 (2017)
- Tsuchido Y, "Real-time quantitative PCR analysis of endoscopic biopsies for diagnosing CMV gastrointestinal disease in non-HIV immunocompromised patients : a diagnostic accuracy study", Eur J Clin Microbiol Infect Dis, 37, pp.2389~2396 (2018)
- Kredel LI, "Accuracy of diagnostic tests and a new algorithm for diagnosing cytomegalovirus colitis in inflammatory bowel diseases : a diagnostic study", Int J Colorectal Dis, 34, pp.229~237 (2019)
- Tandon P, "Diagnostic accuracy of blood-based tests and histopathology for cytomegalovirus reactivation in inflammatory bowel disease : a systematic review and meta-analysis", Inflamm Bowel Dis, 23, pp.551~560 (2017)
- Liao X, "Strategy vaccination against hepatitis B in China", Hum Vaccin Immunother, 11, pp.1534~1539 (2015)
- Nishimura K, "Comparison of two hepatitis B vaccination strategies targeting vertical transmission:a 10-year Japanese multicenter prospective cohort study", Vaccines(Basel), 9, pp.58~ (2021)
- Cho EJ, "Current status and strategies for hepatitis B control in Korea", Clin Mol Hepatol, 23, pp.205~211 (2017)
- Huang ML, "Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China : a retrospective study", J Crohns Colitis, 8, pp.282~287 (2014)
- Chen D, "Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China", Eur J Gastroenterol Hepatol, 29, pp.509~515 (2017)
- Soo-Kyung Park, "Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases", Intestinal research, 18(1), pp.18~33 (2020), 대한장연구학회
- Choon Jin Ooi, "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia", Intestinal research, 17(3), pp.285~310 (2019), 대한장연구학회[DOI]
- Ben Musa R, "Hepatitis B vaccination in patients with inflammatory bowel disease", World J Gastroenterol, 20, pp.15358~15366 (2014)
- Kaneko T, "Clostridium difficile infection in patients with ulcerative colitis : investigations of risk factors and efficacy of antibiotics for steroid refractory patients", Clin Res Hepatol Gastroenterol, 35, pp.315~320 (2011)
- Nitzan O, "Clostridium difficile and inflammatory bowel disease : role in pathogenesis and implications in treatment", World J Gastroenterol, 19, pp.7577~7585 (2013)
- Expert Committee of Laboratory Physicians of Infectious Disease, "Expert consensus on diagnosis and treatment of Clostridium difficile infection in Chinese adults", Med J PUMCH, 8, pp.131~138 (2017)
- Consensus expert group of “Modern Digestive and Interventional Diagnosis and Treatment”, "Expert consensus on the management of inflammatory bowel disease with Clostridium difficile infection in Chinese adults", Mod Dig Intervention, 24, pp.448~452 (2019)
- McDonald LC, "Clinical practice guidelines for Clostridium difficile infection in adults and children : 2017 update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA)", Clin Infect Dis, 66, pp.987~994 (2018)
- Kelly CR, "ACG clinical guidelines : prevention, diagnosis, and treatment of Clostridioides difficile infections", Am J Gastroenterol, 116, pp.1124~1147 (2021)
- Johnson S, "Clinical practice guideline by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA) : 2021 focused update guidelines on management of Clostridioides difficile infection in adults", Clin Infect Dis, 73, pp.e1029~e1044 (2021)
- Appaneal HJ, "What is the role for metronidazole in the treatment of Clostridium difficile infection? Results from a national cohort study of veterans with initial mild disease", Clin Infect Dis, 69, pp.1288~1295 (2019)
- Imwattana K, "Mild or malign : clinical characteristics and outcomes of Clostridium difficile infection in Thailand", J Clin Microbiol, 58, pp.e01217~e01220 (2020)
- Adelman MW, "Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018", Anaerobe, 70, pp.102364~ (2021)
- Clancy CJ, "Impact of revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America clinical practice guidelines on the treatment of Clostridium difficile infections in the United States", Clin Infect Dis, 72, pp.1944~1949 (2021)